NUVA Stock Overview
NuVasive, Inc., a medical technology company, develops, manufactures, and sells procedural solutions for spine surgery. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 3/6 |
| Past Performance | 1/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
NuVasive, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$39.75 |
| 52 Week High | US$49.53 |
| 52 Week Low | US$35.17 |
| Beta | 1.07 |
| 11 Month Change | -0.63% |
| 3 Month Change | 0.84% |
| 1 Year Change | -8.30% |
| 33 Year Change | -22.24% |
| 5 Year Change | -42.71% |
| Change since IPO | 248.68% |
Recent News & Updates
Recent updates
Is NuVasive (NASDAQ:NUVA) Using Too Much Debt?
Apr 18
What Does NuVasive, Inc.'s (NASDAQ:NUVA) Share Price Indicate?
Jan 24NuVasive, Inc.'s (NASDAQ:NUVA) Intrinsic Value Is Potentially 48% Above Its Share Price
Dec 31Capital Allocation Trends At NuVasive (NASDAQ:NUVA) Aren't Ideal
Dec 05These 4 Measures Indicate That NuVasive (NASDAQ:NUVA) Is Using Debt Reasonably Well
Nov 13Calculating The Intrinsic Value Of NuVasive, Inc. (NASDAQ:NUVA)
Sep 22Capital Allocation Trends At NuVasive (NASDAQ:NUVA) Aren't Ideal
Sep 01NuVasive Likely Undervalued, But It's Hard To Find Catalysts
Aug 17Does NuVasive (NASDAQ:NUVA) Have A Healthy Balance Sheet?
Aug 11NuVasive Non-GAAP EPS of $0.47 misses by $0.09, revenue of $310.5M beats by $4.12M
Aug 03NuVasive: Industry Tailwinds More Than Fairly Priced
Jun 13Calculating The Intrinsic Value Of NuVasive, Inc. (NASDAQ:NUVA)
Jun 01Investors Could Be Concerned With NuVasive's (NASDAQ:NUVA) Returns On Capital
May 11NuVasive (NASDAQ:NUVA) Has A Pretty Healthy Balance Sheet
Apr 20At US$56.32, Is NuVasive, Inc. (NASDAQ:NUVA) Worth Looking At Closely?
Mar 30NuVasive's Turnaround Story Needs A Boost From Better Results
Mar 01Investors Could Be Concerned With NuVasive's (NASDAQ:NUVA) Returns On Capital
Dec 28Should You Think About Buying NuVasive, Inc. (NASDAQ:NUVA) Now?
Dec 02NuVasive (NASDAQ:NUVA) Has A Pretty Healthy Balance Sheet
Nov 11NuVasive, Inc. (NASDAQ:NUVA) Shares Could Be 32% Below Their Intrinsic Value Estimate
Oct 21Be Wary Of NuVasive (NASDAQ:NUVA) And Its Returns On Capital
Sep 29At US$59.79, Is It Time To Put NuVasive, Inc. (NASDAQ:NUVA) On Your Watch List?
Aug 18NuVasive Still Getting No Love With COVID-19 And Competitive Worries
Aug 12Does NuVasive (NASDAQ:NUVA) Have A Healthy Balance Sheet?
Jul 27Are Investors Undervaluing NuVasive, Inc. (NASDAQ:NUVA) By 21%?
Jun 17Some Investors May Be Worried About NuVasive's (NASDAQ:NUVA) Returns On Capital
May 30Why We Think NuVasive, Inc.'s (NASDAQ:NUVA) CEO Compensation Is Not Excessive At All
May 12Is NuVasive (NASDAQ:NUVA) Using Too Much Debt?
Mar 30Is Now The Time To Look At Buying NuVasive, Inc. (NASDAQ:NUVA)?
Mar 09Need To Know: NuVasive, Inc. (NASDAQ:NUVA) Insiders Have Been Buying Shares
Feb 16
A Look At The Fair Value Of NuVasive, Inc. (NASDAQ:NUVA)
Jan 26NuVasive stock gains on study results of its X360 surgery approach
Jan 06What Type Of Returns Would NuVasive's(NASDAQ:NUVA) Shareholders Have Earned If They Purchased Their SharesYear Ago?
Jan 05Shareholder Returns
| NUVA | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | 1.5% | -1.1% | -2.1% |
| 1Y | -8.3% | 22.8% | 30.2% |
Return vs Industry: NUVA underperformed the US Medical Equipment industry which returned -3.3% over the past year.
Return vs Market: NUVA underperformed the US Market which returned 14.1% over the past year.
Price Volatility
| NUVA volatility | |
|---|---|
| NUVA Average Weekly Movement | 3.8% |
| Medical Equipment Industry Average Movement | 8.0% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 15.5% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: NUVA has not had significant price volatility in the past 3 months.
Volatility Over Time: NUVA's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1997 | 3,000 | Chris Barry | www.nuvasive.com |
NuVasive, Inc., a medical technology company, develops, manufactures, and sells procedural solutions for spine surgery. It provides surgical access instruments, including Maxcess integrated split-blade retractor system that enable less-invasive surgical techniques by minimizing soft tissue disruption during spine surgery; specialized spinal implants to advance spinal fusion by enhancing the osseointegration and biomechanical properties of implant materials, including porous titanium and porous polyetheretherketone; and fixation system that facilitates the preservation and restoration of patient alignment. The company also offers cervical total disc replacement technology for cervical spinal fusion surgery; neuromonitoring systems, which use proprietary software-driven nerve detection and avoidance technology, and its intraoperative neuromonitoring services and support; and Pulse platform, a software ecosystem that integrates multiple hardware technologies into a single, condensed footprint in the operating room.
NuVasive, Inc. Fundamentals Summary
| NUVA fundamental statistics | |
|---|---|
| Market cap | US$2.08b |
| Earnings (TTM) | US$28.45m |
| Revenue (TTM) | US$1.23b |
73.3x
P/E Ratio1.7x
P/S RatioIs NUVA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NUVA income statement (TTM) | |
|---|---|
| Revenue | US$1.23b |
| Cost of Revenue | US$347.50m |
| Gross Profit | US$878.73m |
| Other Expenses | US$850.28m |
| Earnings | US$28.45m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.54 |
| Gross Margin | 71.66% |
| Net Profit Margin | 2.32% |
| Debt/Equity Ratio | 89.1% |
How did NUVA perform over the long term?
See historical performance and comparison